REVANCE THERAPEUTICS INC (RVNC) Stock Price, Quote, News and Overview
NASDAQ:RVNC - Nasdaq - US7613301099 - Common Stock
RVNC Quote and Key Statistics
REVANCE THERAPEUTICS INC
NASDAQ:RVNC (1/22/2025, 11:33:23 AM)
3.655
-0.02 (-0.41%)
RVNC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RVNC Performance and Technical Analysis
RVNC Ownership and Analysts
RVNC Latest News and Analysis
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:...
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
/PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that, on January 17, 2025, they...
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares...
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit...
About RVNC
Company Profile
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 597 full-time employees. The company went IPO on 2014-02-06. The firm's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. The company has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The firm has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Company Info
REVANCE THERAPEUTICS INC
1222 Demonbreun Street, Suite 2000
Nashville TENNESSEE 37203 US
CEO: Mark J. Foley
Employees: 597
Company Website: https://www.revance.com/
Investor Relations: https://investors.revance.com
Phone: 16157247755
RVNC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 74.62 | 720.47B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.33 | 359.33B | ||
| JNJ | JOHNSON & JOHNSON | 14.06 | 346.65B | ||
| MRK | MERCK & CO. INC. | 16.16 | 243.16B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.88 | 211.28B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.26 | 197.81B | ||
| PFE | PFIZER INC | 10.25 | 149.86B | ||
| SNY | SANOFI-ADR | 12.37 | 129.06B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.35 | 114.74B | ||
| ZTS | ZOETIS INC | 29.08 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.22 | 68.55B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.62 | 41.12B |